{"id":"viral-ctls","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fever"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Muscle pain"}]},"_chembl":{"chemblId":"CHEMBL2447913","moleculeType":"Small molecule","molecularWeight":"456.26"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Viral CTLs work by activating cytotoxic T lymphocytes, a type of immune cell that recognizes and kills infected cells. This process helps to eliminate the virus from the body. The exact mechanism of action may vary depending on the specific viral infection being targeted.","oneSentence":"Viral CTLs stimulate the body's immune response to fight viral infections.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:35.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza"},{"name":"Human immunodeficiency virus (HIV)"},{"name":"Herpes simplex virus (HSV)"},{"name":"Human papillomavirus (HPV)"}]},"trialDetails":[{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT07225972","phase":"PHASE3","title":"Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone","status":"NOT_YET_RECRUITING","sponsor":"New York Medical College","startDate":"2026-12-01","conditions":"CMV, AdV Infection, AdV Reactivation","enrollment":69},{"nctId":"NCT05101213","phase":"PHASE1","title":"Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-01-06","conditions":"Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection","enrollment":30},{"nctId":"NCT03266627","phase":"PHASE2","title":"Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2018-11-01","conditions":"Adenovirus, Primary Immune Deficiency Disorder","enrollment":20},{"nctId":"NCT03266640","phase":"PHASE2","title":"Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2018-11-01","conditions":"Cytomegalovirus Infections, Primary Immune Deficiency Disorder","enrollment":20},{"nctId":"NCT05564598","phase":"PHASE2","title":"CMV CTLs in Neonates With CMV Infection","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2023-07-01","conditions":"Congenital Cytomegaloviral (CMV) Disease","enrollment":23},{"nctId":"NCT04742595","phase":"EARLY_PHASE1","title":"Viral Specific T Cell Therapy for COVID-19 Related Pneumonia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-18","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":32},{"nctId":"NCT04056533","phase":"PHASE2","title":"Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy","status":"RECRUITING","sponsor":"Instituto de Investigación Marqués de Valdecilla","startDate":"2022-03-26","conditions":"CMV","enrollment":15},{"nctId":"NCT03004261","phase":"PHASE4","title":"CMV-CTL for the Treatment of CMV Infection After HSCT","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-11","conditions":"Cytomegalovirus Infections, Hematological Disease","enrollment":5},{"nctId":"NCT01646645","phase":"PHASE2","title":"Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-07-13","conditions":"Cytomegalovirus","enrollment":58},{"nctId":"NCT02779439","phase":"PHASE1","title":"Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation","status":"UNKNOWN","sponsor":"University of Sydney","startDate":"2013-01","conditions":"CMV Infection, EBV, Adenovirus","enrollment":25},{"nctId":"NCT01945619","phase":"","title":"Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)","status":"NO_LONGER_AVAILABLE","sponsor":"Baylor College of Medicine","startDate":"","conditions":"EBV Infection, CMV Infection, Adenoviral Infection","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Viral CTLs","genericName":"Viral CTLs","companyName":"New York Medical College","companyId":"new-york-medical-college","modality":"Biologic","firstApprovalDate":"","aiSummary":"Viral CTLs stimulate the body's immune response to fight viral infections. Used for Influenza, Human immunodeficiency virus (HIV), Herpes simplex virus (HSV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}